Article ID Journal Published Year Pages File Type
6087396 Clinical Immunology 2015 9 Pages PDF
Abstract

•We firstly report that ChgA-specific CD8+ T cells were present in humanized NOD mice and T1D patients.•ChgA10-19 and ChgA43-52 were identified as novel HLA-A*0201-restricted CD8+ T-cell epitopes.•mChgA10-19 and mChgA43-52 stimulated the production of IFN-γ, perforin, and IL-17.

ChgA has recently been identified as the autoantigen for diabetogenic CD4+ T cells in NOD mice and T1D patients. However, autoreactive CD8+ T-cell responses targeting ChgA haven't been studied yet. Here several HLA-A*0201-restricted peptides derived from mChgA and hChgA were selected by an integrated computational prediction approach, followed by an HLA-A*0201 binding assay. MChgA10-19 and mChgA43-52 peptides, which bound well with HLA-A*0201 molecule, induced significant proliferation and IFN-γ-releasing of splenocytes from diabetic NOD.β2mnull.HHD mice. Notably, flow cytometry analysis found that mChgA10-19 and mChgA43-52 stimulated the production of IFN-γ, perforin, and IL-17 by splenic CD8+ T cells of diabetic NOD.β2mnull.HHD mice. Furthermore, hChgA10-19 and hChgA43-52-induced IFN-γ releasing by specific CD8+ T cells were frequently detected in recent-onset HLA-A*0201-positive T1D patients. Thus, this study demonstrated that autoreactive CD8+ T cells targeting ChgA were present in NOD.β2mnull.HHD mice and T1D patients, and might contribute to pathogenesis of T1D through secreting proinflammatory cytokines and cytotoxic molecules.

Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , , , , ,